Nelistotug

Product Description

A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor CD96 (Tactile; T cell activation increased late expression), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CD96 monoclonal antibody GSK6097608 targets, binds to and inhibits CD96 expressed primarily on T-cells and natural killer (NK) cells, thereby preventing its downstream signaling pathways. This may abrogate CD96-mediated inhibition of T-cell and NK cell effector function and may restore immune function and anti-tumor immune responses through the activation of T-cells and NKs. This may kill and inhibit growth of tumor cells. CD96, a type I transmembrane glycoprotein of the immunoglobulin superfamily and immunological checkpoint for CD8+ T-cells and NK cells, negatively regulates T-cell and NK cell activation and is overexpressed in a variety of cancer settings. (Sourced from: https://www.mycancergenome.org/content/drugs/gsk6097608/)

Mechanisms of Action: CD98 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None